table of content
1 Prostate Cancer Chemotherapy Drugs Market Overview
1.1 Product Overview and Scope of Prostate Cancer Chemotherapy Drugs
1.2 Prostate Cancer Chemotherapy Drugs Segment by Type
1.2.1 Global Prostate Cancer Chemotherapy Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Abiraterone Acetate
1.2.3 Apalutamide
1.2.4 Bicalutamide
1.2.5 Cabazitaxel
1.2.6 Others
1.3 Prostate Cancer Chemotherapy Drugs Segment by Application
1.3.1 Global Prostate Cancer Chemotherapy Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Sales
1.3.5 Other
1.4 Global Prostate Cancer Chemotherapy Drugs Market Size Estimates and Forecasts
1.4.1 Global Prostate Cancer Chemotherapy Drugs Revenue 2017-2028
1.4.2 Global Prostate Cancer Chemotherapy Drugs Sales 2017-2028
1.4.3 Prostate Cancer Chemotherapy Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Prostate Cancer Chemotherapy Drugs Market Competition by Manufacturers
2.1 Global Prostate Cancer Chemotherapy Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Prostate Cancer Chemotherapy Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Prostate Cancer Chemotherapy Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Prostate Cancer Chemotherapy Drugs Manufacturing Sites, Area Served, Product Type
2.5 Prostate Cancer Chemotherapy Drugs Market Competitive Situation and Trends
2.5.1 Prostate Cancer Chemotherapy Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Prostate Cancer Chemotherapy Drugs Players Market Share by Revenue
2.5.3 Global Prostate Cancer Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Prostate Cancer Chemotherapy Drugs Retrospective Market Scenario by Region
3.1 Global Prostate Cancer Chemotherapy Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Prostate Cancer Chemotherapy Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country
3.3.1 North America Prostate Cancer Chemotherapy Drugs Sales by Country
3.3.2 North America Prostate Cancer Chemotherapy Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country
3.4.1 Europe Prostate Cancer Chemotherapy Drugs Sales by Country
3.4.2 Europe Prostate Cancer Chemotherapy Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Prostate Cancer Chemotherapy Drugs Sales by Region
3.5.2 Asia Pacific Prostate Cancer Chemotherapy Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country
3.6.1 Latin America Prostate Cancer Chemotherapy Drugs Sales by Country
3.6.2 Latin America Prostate Cancer Chemotherapy Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Prostate Cancer Chemotherapy Drugs Sales by Country
3.7.2 Middle East and Africa Prostate Cancer Chemotherapy Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Prostate Cancer Chemotherapy Drugs Historic Market Analysis by Type
4.1 Global Prostate Cancer Chemotherapy Drugs Sales Market Share by Type (2017-2022)
4.2 Global Prostate Cancer Chemotherapy Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Prostate Cancer Chemotherapy Drugs Price by Type (2017-2022)
5 Global Prostate Cancer Chemotherapy Drugs Historic Market Analysis by Application
5.1 Global Prostate Cancer Chemotherapy Drugs Sales Market Share by Application (2017-2022)
5.2 Global Prostate Cancer Chemotherapy Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Prostate Cancer Chemotherapy Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Johnson & Johnson Prostate Cancer Chemotherapy Drugs Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Pfizer Prostate Cancer Chemotherapy Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Roche Prostate Cancer Chemotherapy Drugs Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Novartis Prostate Cancer Chemotherapy Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 AbbVie
6.5.1 AbbVie Corporation Information
6.5.2 AbbVie Description and Business Overview
6.5.3 AbbVie Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 AbbVie Prostate Cancer Chemotherapy Drugs Product Portfolio
6.5.5 AbbVie Recent Developments/Updates
6.6 Bristol-Myer
6.6.1 Bristol-Myer Corporation Information
6.6.2 Bristol-Myer Description and Business Overview
6.6.3 Bristol-Myer Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Bristol-Myer Prostate Cancer Chemotherapy Drugs Product Portfolio
6.6.5 Bristol-Myer Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sanofi Prostate Cancer Chemotherapy Drugs Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 AstraZeneca Prostate Cancer Chemotherapy Drugs Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Merck
6.9.1 Merck Corporation Information
6.9.2 Merck Description and Business Overview
6.9.3 Merck Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Merck Prostate Cancer Chemotherapy Drugs Product Portfolio
6.9.5 Merck Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Amgen Prostate Cancer Chemotherapy Drugs Product Portfolio
6.10.5 Amgen Recent Developments/Updates
6.11 Bayer AG
6.11.1 Bayer AG Corporation Information
6.11.2 Bayer AG Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.11.3 Bayer AG Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Bayer AG Prostate Cancer Chemotherapy Drugs Product Portfolio
6.11.5 Bayer AG Recent Developments/Updates
6.12 Ipsen Group
6.12.1 Ipsen Group Corporation Information
6.12.2 Ipsen Group Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.12.3 Ipsen Group Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Ipsen Group Prostate Cancer Chemotherapy Drugs Product Portfolio
6.12.5 Ipsen Group Recent Developments/Updates
6.13 Endo Pharmaceuticals
6.13.1 Endo Pharmaceuticals Corporation Information
6.13.2 Endo Pharmaceuticals Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.13.3 Endo Pharmaceuticals Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Endo Pharmaceuticals Prostate Cancer Chemotherapy Drugs Product Portfolio
6.13.5 Endo Pharmaceuticals Recent Developments/Updates
6.14 Dendreon Corporation
6.14.1 Dendreon Corporation Corporation Information
6.14.2 Dendreon Corporation Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.14.3 Dendreon Corporation Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Dendreon Corporation Prostate Cancer Chemotherapy Drugs Product Portfolio
6.14.5 Dendreon Corporation Recent Developments/Updates
6.15 Myovant Biosciences
6.15.1 Myovant Biosciences Corporation Information
6.15.2 Myovant Biosciences Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.15.3 Myovant Biosciences Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Myovant Biosciences Prostate Cancer Chemotherapy Drugs Product Portfolio
6.15.5 Myovant Biosciences Recent Developments/Updates
6.16 Effector Therapeutics
6.16.1 Effector Therapeutics Corporation Information
6.16.2 Effector Therapeutics Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.16.3 Effector Therapeutics Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Effector Therapeutics Prostate Cancer Chemotherapy Drugs Product Portfolio
6.16.5 Effector Therapeutics Recent Developments/Updates
6.17 Mediolanum
6.17.1 Mediolanum Corporation Information
6.17.2 Mediolanum Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.17.3 Mediolanum Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Mediolanum Prostate Cancer Chemotherapy Drugs Product Portfolio
6.17.5 Mediolanum Recent Developments/Updates
6.18 ESSA Pharma
6.18.1 ESSA Pharma Corporation Information
6.18.2 ESSA Pharma Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.18.3 ESSA Pharma Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.18.4 ESSA Pharma Prostate Cancer Chemotherapy Drugs Product Portfolio
6.18.5 ESSA Pharma Recent Developments/Updates
6.19 Astellas Pharma
6.19.1 Astellas Pharma Corporation Information
6.19.2 Astellas Pharma Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.19.3 Astellas Pharma Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Astellas Pharma Prostate Cancer Chemotherapy Drugs Product Portfolio
6.19.5 Astellas Pharma Recent Developments/Updates
6.20 Janssen
6.20.1 Janssen Corporation Information
6.20.2 Janssen Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.20.3 Janssen Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Janssen Prostate Cancer Chemotherapy Drugs Product Portfolio
6.20.5 Janssen Recent Developments/Updates
6.21 Eli Lilly and Company
6.21.1 Eli Lilly and Company Corporation Information
6.21.2 Eli Lilly and Company Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.21.3 Eli Lilly and Company Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Eli Lilly and Company Prostate Cancer Chemotherapy Drugs Product Portfolio
6.21.5 Eli Lilly and Company Recent Developments/Updates
6.22 POINT Biopharma
6.22.1 POINT Biopharma Corporation Information
6.22.2 POINT Biopharma Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.22.3 POINT Biopharma Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.22.4 POINT Biopharma Prostate Cancer Chemotherapy Drugs Product Portfolio
6.22.5 POINT Biopharma Recent Developments/Updates
6.23 Hinnova Pharmaceuticals
6.23.1 Hinnova Pharmaceuticals Corporation Information
6.23.2 Hinnova Pharmaceuticals Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.23.3 Hinnova Pharmaceuticals Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Hinnova Pharmaceuticals Prostate Cancer Chemotherapy Drugs Product Portfolio
6.23.5 Hinnova Pharmaceuticals Recent Developments/Updates
6.24 Sophiris Bio
6.24.1 Sophiris Bio Corporation Information
6.24.2 Sophiris Bio Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.24.3 Sophiris Bio Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Sophiris Bio Prostate Cancer Chemotherapy Drugs Product Portfolio
6.24.5 Sophiris Bio Recent Developments/Updates
6.25 Ultimovacs
6.25.1 Ultimovacs Corporation Information
6.25.2 Ultimovacs Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.25.3 Ultimovacs Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Ultimovacs Prostate Cancer Chemotherapy Drugs Product Portfolio
6.25.5 Ultimovacs Recent Developments/Updates
6.26 Foresee Pharmaceuticals
6.26.1 Foresee Pharmaceuticals Corporation Information
6.26.2 Foresee Pharmaceuticals Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.26.3 Foresee Pharmaceuticals Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Foresee Pharmaceuticals Prostate Cancer Chemotherapy Drugs Product Portfolio
6.26.5 Foresee Pharmaceuticals Recent Developments/Updates
6.27 Luye Pharma Group
6.27.1 Luye Pharma Group Corporation Information
6.27.2 Luye Pharma Group Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.27.3 Luye Pharma Group Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.27.4 Luye Pharma Group Prostate Cancer Chemotherapy Drugs Product Portfolio
6.27.5 Luye Pharma Group Recent Developments/Updates
6.28 Abbott
6.28.1 Abbott Corporation Information
6.28.2 Abbott Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.28.3 Abbott Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.28.4 Abbott Prostate Cancer Chemotherapy Drugs Product Portfolio
6.28.5 Abbott Recent Developments/Updates
6.29 Jiangsu HengRui Medicine
6.29.1 Jiangsu HengRui Medicine Corporation Information
6.29.2 Jiangsu HengRui Medicine Prostate Cancer Chemotherapy Drugs Description and Business Overview
6.29.3 Jiangsu HengRui Medicine Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.29.4 Jiangsu HengRui Medicine Prostate Cancer Chemotherapy Drugs Product Portfolio
6.29.5 Jiangsu HengRui Medicine Recent Developments/Updates
7 Prostate Cancer Chemotherapy Drugs Manufacturing Cost Analysis
7.1 Prostate Cancer Chemotherapy Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Prostate Cancer Chemotherapy Drugs
7.4 Prostate Cancer Chemotherapy Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Prostate Cancer Chemotherapy Drugs Distributors List
8.3 Prostate Cancer Chemotherapy Drugs Customers
9 Prostate Cancer Chemotherapy Drugs Market Dynamics
9.1 Prostate Cancer Chemotherapy Drugs Industry Trends
9.2 Prostate Cancer Chemotherapy Drugs Market Drivers
9.3 Prostate Cancer Chemotherapy Drugs Market Challenges
9.4 Prostate Cancer Chemotherapy Drugs Market Restraints
10 Global Market Forecast
10.1 Prostate Cancer Chemotherapy Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Prostate Cancer Chemotherapy Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Prostate Cancer Chemotherapy Drugs by Type (2023-2028)
10.2 Prostate Cancer Chemotherapy Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Prostate Cancer Chemotherapy Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Prostate Cancer Chemotherapy Drugs by Application (2023-2028)
10.3 Prostate Cancer Chemotherapy Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Prostate Cancer Chemotherapy Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Prostate Cancer Chemotherapy Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
